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Rheumatoid factors (RF) have been classically defined as anti-IgG antibodies, 
usually of the IgM class,  found in the sera of people afflicted with rheumatoid 
arthritis  or  a  number  of other  autoimmune diseases  (1-3).  Antibodies  with 
properties similar to these can be found in mice that display no pathology. We 
have proposed  that  such immune complex-specific antibodies be  termed "en- 
hancing antibodies" because of their ability to augment antibody:antigen inter- 
actions and because we believe that in most cases such antibodies arise normally, 
produce no concurrent pathogenesis, and may be able to aid in antigen elimina- 
tion (4).  In this scheme rheumatoid factors represent a subset of the enhancing 
antibodies produced against immune complexes. Others include those that react 
with new determinants or combinations of determinants generated by the close 
juxtaposition of antibody and antigen or conformational changes in the antigen 
due to bound antibody. 
In some mouse strains,  production of auto-anti-IgG is associated with rheu- 
matoid arthritis- or lupus erythematosis-like syndromes (5,  6).  In other strains 
RF-like material is produced in the absence of obvious disease.  Strain  129/Sv 
mice,  for example, appear  to  produce  RF-like  antibody in  response  to  some 
unknown environmental stimulus in an age-dependent manner (7, 8). Mice that 
do not normally produce autoreactive anti-IgG in  detectable amounts can be 
induced to do so by a  number of reagents that are known to be nonspecific B 
cell activators, e.g. lipopolysaccharide (LPS) (9-12). In this study we have focused 
on enhancing antibody production and specificity in A/J mice. We show that in 
mice that do not spontaneously produce detectable amounts of auto-anti-IgG, 
very large amounts can be induced by repeated immunization with virtually any 
antigen  and  the  antibody  produced is  of highly restricted  specificity. These 
results confirm and extend previous work (13-15) that suggested that RF-like 
antibodies are produced in  vivo in response to the presence of immune com- 
plexes. 
Abbreviations used in this paper: Ars, p-azophenyl arsonate; BSA,  bovine serum albumin; CFA, 
complete Freund's adjuvant; DNP, dinitrophenyl; KLH, Keyhole Limpet hemocyanin; LPH, Limulus 
polyphemus hemocyanin;  LPS,  lipopolysaccharide; NIP,  (4-hydroxy-5-iodo-3-nitrophenyl) acetyl; 
OVA, ovalbumin; PFC, plaque-forming cell; RF, rheumatoid factor; SRBC, sheep erythrocytes. 
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Materials and  Methods 
Mice and  Immunizations.  A/J  mice were purchased  from Jackson  Laboratories,  Bar 
Harbor, ME. BALB/c and C57B 1/6 mice were obtained from Charles River Laborato- 
ries, Wilmington, MA. (A/J x  BALB/c) mice were bred in the Animal Facilities of the 
Biological Laboratories, Harvard University. In most cases primary immunizations were 
done with the protein antigen emulsified in an equal volume of  complete Freund's adjuvant 
(CFA).  Mice  received  0.2  mg of protein  emulsion  in  a  total  volume of 0.2  ml.  For 
secondary immunizations, 30 #g of protein was suspended in 200 pl saline and injected 
intraperitoneally. 
Antigen Preparation.  Ars27LPH was prepared according to a standard procedure (16). 
DNPvKLH was prepared following the method described in (17).  OVA was purchased 
from Sigma Chemical, St. Louis, MO. 
Hapten-coupled Erythrocytes.  Ars-coupled sheep erythrocytes (SRBC) were prepared as 
described in (18).  The final reaction mixture contains  20 mM  Ars diazonium salt,  2% 
borate (wt/vol)-PBS, pH 8.2, and 25% (vol/vol) SRBC. After a 45-rain incubation on ice 
the cells are washed in PBS.  NIP-coupling was done as described in (19).  1 mg of NIP-O- 
succinamide (Biosearch, San Rafael, CA) is added per 1 ml 20% (vol/vol) SRBC in borate- 
PBS, pH 8.2 and incubated for  I0 min at room temperature.  OVA-coupled cells were 
prepared following the chromium chloride method (20).  Briefly, to an equal volume of 
packed, saline-washed SRBC is added one volume of 10 mg/ml OVA and one volume of 
2 mg/ml CrCI~. The mixture is incubated  10 min at room temperature and washed in 
saline. Coupled erythrocytes were stored in phosphate-buffered saline,  1%  dextrose at 
4°C. 
Monoclonal Anti-hapten Antibodies.  id77 (3'2a,K) and 423E2 (3q,K) are anti-Ars-specific 
proteins from hybridomas isolated in our laboratory. 36-71  (y2,K),  31-62 (~,~a,K), and 
45-278  ('ys,K)  are  Ars-specific  monoclonal  antibodies  that  were  kindly  provided  by 
Professor Marshak-Rothstein of Boston University Medical School (21).  All of the Ars- 
specific hybridoma proteins were derived from A/J mice and all except 423E2 bear the 
major cross-reactive anti-Ars  idiotype  (22).  D6.582  (~q,K)  is  an  anti-NIP  monoclonal 
protein derived from a C57B1/6 (Ig  b) mouse spleen cell.  It was generously provided by 
Professor Imanishi-Kari of MIT. All of the above-mentioned anti-Ars hybridoma proteins 
were affinity-purified on LPH-Ars-Sepharose 4B. The anti-NIP monoclonal was affinity- 
purified on OVA-NIP-Sepharose 4B. 
Monoclonal Anti-IgG1  Antibodies.  Four rat anti-IgG1 antibodies with  RF-like activity, 
designated  22C9,  24C5,  24D3,  and  25Cll,  have been  described  elsewhere  (4).  The 
hybridoma 411H (3"s,K) was derived from the fusion of SP 2/0-Ag-14 myeloma cells (23) 
with the spleen cells of an A/J mouse hyperimmunized with LPH-Ars. G (#,?) and R (#,?) 
were produced by the fusion of the myeloma cells with the spleen cells of KLH-penicillin 
hyperimmunized  Balb/c  mice.  G,  R,  P,  and  Y  were  produced  in  collaboration  with 
Angenics, Inc. (Cambridge, MA). All monoclonal antibodies were detected by their ability 
to bind to antigen:antibody complexes. In the case of 411 H, x~SI-labeled LPH-Ars:anti- 
Ars complexes were used; for R, G, Y, and P,  125I-BSA:anti-BSA complexes were used. 
Hybridoma culture supernatants were applied to polyvinyl chloride wells coated with 50 
pl/weli specific rabbit anti-mouse Ig as described in (4).  After a 2-4-h incubation, anti- 
mouse Ig sites were blocked by incubation with 1% normal mouse serum for 1 h and then 
20,000 cpm of labeled complexes were applied per well in 50 pl of saline supplemented 
with  1  mg/ml  BSA  and  1%  normal  mouse  serum.  After  2  h  the  wells  were  washed 
extensively in water, cut apart, and the bound radioactivity was measured. 
Hemagglutination Assay.  To measure anti-Ig activity of serum samples, hapten-coupled 
SRBC were sensitized with anti-hapten antibodies of any of the IgG isotypes. Antibody 
samples to be tested were serially twofold diluted  in saline-l% BSA and 50-~1 aliquots 
were placed into 96-well microtiter trays. An equal volume of the SRBC solution contain- 
ing 0.4% hapten-SRBC,  1/~g/ml monoclonal anti-hapten antibody, and 1% dextrose was 
added to each microtiter well.  After mixing, the cells were allowed to settle overnight at 
4°C.  For anti-OVA  hemagglutination  measurements the  SRBC  solution  contained no 
additional antibody and the cells were OVA-coupled. All antisera were heat inactivated NEMAZEE AND SATO  531 
(56 °, 30 min) before use. 
Plaque Assay.  We modified the procedure of Cunningham (24) for use in detecting 
anti-IgG PFC. Equal volumes of 15% (vol/vol) hapten-SRBC, diluted anti-hapten mono- 
cional antibody, and fourfold diluted guinea pig serum as a source of complement, were 
added tO one volume of the antibody-forming cell suspension to be tested. This mixture 
was pipetted into glass slide chambers, sealed, and incubated at 37 ° for 30-35 rain. Slides 
were scored for plaques by visualization under a stereoscopic dissecting microscope at 7× 
magnification.  40 #g/mi monoclonai antibody was used for most of the assays with the 
exception of 36-71, which developed plaques maximally at a concentration of 20 #g/ml. 
In some experiments mildly reduced and alkylated anti-hapten antibody was used. Anti- 
bodies  (1  mg/ml in  PBS) were reduced by addition of dithiothreitol to  10 mM and 
incubated for 30 mifi at 37°C. Aikylation was carried out on these samples by addition of 
10% molar excess of iodoacetamide. 
Results 
Plaque Assay  for BF-like  Enhancing Antibodies.  We developed a hemolytic plaque 
assay that detects anti-IgG producing cells with specificity for any of the mouse 
IgG isotypes. To an aliquot of hapten-modified target erythrocytes is added an 
appropriate  concentration  of a  monoclonal  antibody  with  specificity for  the 
hapten. The isotype of the antibody can be varied by choosing from a panel of 
anti-hapten antibodies of different isotypes. The target cells are thus effectively 
coated with  antibody of defined isotype.  To  this  mixture is  added antibody- 
forming cells to be tested and guinea pig complement. The rest of the procedure 
is essentially identical to the slide method of Cunningham (24).  Plaques can be 
scored after a 30-rain incubation at 37°C. In the experiments described here the 
haptens chosen to modify erythrocytes (Ars, NIP) were unrelated to the antigens 
used to immunize mice, thus the background levels of plaques detected in the 
absence of anti-hapten antibody were small. 
We have found that the concentrations of antibodies, used to coat cells, which 
allow maximal plaque detection are sufficiently low that target cell aggregation 
is not a problem. Complement fixing monoclonals, i.e. IgG2a, IgG2b, and IgG3, 
must be mildly reduced and alkylated before cell coating to prevent spontaneous 
target cell  lysis.  This  treatment destroys the complement-fixing ability of the 
antibody, but appears not to affect RF binding (25, 26). As in standard hemolytic 
plaque assays, only IgM producing cells are visualized in the absence of "devel- 
oping" anti-mouse Ig antiserum. To detect IgG3 anti-IgG1 producing cells, for 
example, it is necessary to add rabbit anti-Ig3 serum to the assay mixture. 
Fig.  1 illustrates the dependence of anti-IgG plaque detection on the concen- 
tration of monoclonal IgG used to coat the SRBC.  In this experiment, spleen 
cells from either hyperimmune A/J to hyperimmune 129/J mice were used as 
sources of anti-IgG-producing cells. (Comparisons of the anti-IgG responses of 
these two mouse strains is the subject of a separate report [Nemazee and Sato, 
manuscript in preparation].) The fact that the number of plaques detected does 
not drop in the presence of very large amounts of antibody suggests that most 
autoanti-IgG  plaque-forming cells  produce antibody  that  preferentially binds 
IgG  that  is  bound  to  the  cells.  The  inhibition  experiment shown  in  Fig.  4 
confirms this point.  Also shown in Fig.  1 is the result that mild reduction and 
alkylation of IgG1  used to coat cells does not effect the number of anti-IgG1 
PFC detected by this method. Thus it appears that in A/J mice that have been 532  ENHANCING  ANTIBODY  INDUCTION  IN  MICE 
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FIGURE  1.  Anti-IgG  plaques  detected  as  a  function  of  IgG  used  to  coat  erythrocytes. 
Immunoglobulin used to coat cells: IgG4  a (O), reduced and alkylated Ig4  a (O), F(ab)'2-Ig4  a (&), 
Ig4  b (1"3), IgG2a (I).  Spleen cells producing anti-IgG1  were obtained  from  A/J mice (vide 
infra). Cells producing anti-IgG2a were from 129/J mice (7). 
hyperimmunized the bulk of the anti-IgG1  producing cells cannot distinguish 
between native and reduced-and-alkylated IgG. 
Induction  of RF PFC with Secondary Antigen  Stimulation.  Unimmunized A/J 
mice normally produce little or no autoanti-IgG as detected by hemagglutination, 
plaque  assay,  and  radioassay  (this  study  and  reference  27).  We  have  never 
observed significant numbers of anti-IgG PFC in mice of this strain of any age. 
We suspected that hyperimmunization with an antigen could induce production 
of RF-like material in these mice. Therefore we looked for anti-IgG PFC in the 
spleens  of  A/J  mice  at  various  times  subsequent  to  primary  or  secondary 
immunization with a variety of protein antigens. No significant anti-IgG response 
was observed  in  mice injected once with either  OVA  or  DNP7KLH  in  CFA, 
soluble  DNP7KLH,  or  CFA  alone.  However,  secondary  stimulation  with 
DNP7KLH  in  primed animals yielded massive and  rapid  IgM  anti-IgG1  PFC 
responses that peaked on day 3 (Fig. 2). We detected little or no autoanti-IgG2a, 
-IgG2b, or -IgG3 in these animals. In these experiments anti-IgG producing PFC 
of only the IgM class were monitored. The anti-DNP  PFC responses of these 
mice were large and included large amounts of IgG1,  IgG2a, and IgG2b class 
PFC (Fig. 3). It appears clear from this experiment that a very large fraction of 
the total number of antibody forming cells of these mice is producing autoanti- 
IgG1  3 d after secondary antigen stimulation. 
Sera from the mice shown to produce large numbers of autoanti-IgG1  PFC 
were tested for the ability to agglutinate IgGl-coated erythrocytes. Fig.  1 shows 
that the peak of the agglutinating response occurs a  few days after the peak of 
the PFC response. (The same is true of the anti-DNP hemagglutinating response 
[Fig. 3].) Using a monoclonal rat IgM anti-IgG1 standard we have estimated that 
the  peak  anti-IgG1  titers  represent  a  concentration  of "~25-100  ug/ml  RF. 
Table  I  shows that sera,  derived from test animals,  containing the  maximum 
amount of anti-IgG1  hemagglutinating activity contain no anti-IgG2a  activity, NEMAZEE  AND  SATO  533 
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FIGURE 2.  Kinetics of production of anti-IgG1 PFC and hemagglutinating activity in A/J 
mice following  secondary immunization with DNPTKLH. Mice were given a primary dose of 
200 #g DNPTKLH  in CFA 2 mo before a boosting injection of 30 #g in PBS. The results from 
two separate experiments are shown: experiment  1 (open symbols), experiment 2 (closed 
symbols). PFC responses (squares), serum anti-IgG1 titers (triangles). Each point represents 
the mean value from three mice. 
thus confirming our plaque assay results. 
The  fact that anti-IgG is not induced upon  primary immunization suggests 
strongly that DNPTKLH is not behaving like a polyclonal B cell activator. Such 
compounds  induce  RF  production  after  a  single  injection.  Most  likely 
IgG1 :antigen complexes  stimulate  the  production  of the  enhancing antibody. 
These  would  not be  present  after a  single  injection  since  the  early antibody 
response to DNP7KLH is predominantly IgM (data not shown),  however they 
would appear upon secondary antigenic exposure. 
In order to confirm that DNPTKLH does not induce autoanti-IgG production 
directly we immunized A/J mice with either DNPTKLH or OVA and boosted 
the mice some weeks later with one of these two antigens. Splenic E-PFC, specific 
for IgG1, were measured 3 d  after the booster injections. Table II shows that 
only mice that were boosted with the same antigen as that used for the initial 534  ENHANCING  ANTIBODY  INDUCTION  IN  MICE 
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FIGURE 3.  Mice producing IgM anti-lgG1 after secondary immunization  to DNP-KLH make 
a  predominantly IgG  response  to  DNP.  Spleen  cells  tested  for  anti-IgGl  PFC  (Fig.  2, 
experiment 1) were assayed for levels of anti-DNP PFC of various isotypes:  IgGl (A), lgG2a 
(A), IgG2b (17), IgG3 (.), IgM (<>). Sera from these mice were taken and tested for anti-DNP 
hemagglutinating  activity (0). 
TABLE  I 
Anti-lgG1 Hemagglutinating Activity in Twice-immunized  A/J Mice 
Hemagglutination titer vs. cells coated 
Days post boost*  with: 
IgGl (Ig4  a)  (Ig4  b)  igG2a 
0  <2  <2  <2 
13  2,048  512  <2 
100 #g/ml 22C9'  4,096  4,096  0 
* Mice were immunized intraperitoneally with 200 #g of DNP~KLH in 
CFA. After 2 mo, mice were boosted with 30 ~tg DNPTKLH in saline. 
Groups of three mice were bled and serum collected on various days 
after the boosting injection. 
* 22C9 is the designation of a  monoclonal rat IgM anti-IgG1 antibody. 
The antibody was purified from ascites by precipitation in 50% saturated 
ammonium sulphate and precipitation in 20 mM Na phosphate, pH 7.5. NEMAZEE  AND  SATO  535 
immunization produced detectable anti-IgG 1. Similar results were obtained with 
C57B1/6, BALB/c, and (A/J × BALB/c)F1 mice (Table II). 
Spec~city ofAnti-IgG 1 Antibody.  Plaque inhibition experiments were performed 
to  further define the  specificity of the enhancing antibody (Fig.  4).  In these 
experiments, A/J mice were induced to produce IgM anti-IgG1 by two rounds 
of immunizations with OVA.  Heat aggregated IgG1  could completely inhibit 
anti-IgG1  plaques, whereas unaggregated IgG1  could not.  Detection of back- 
ground plaques specific for the hapten NIP were unaffected by heat aggregated 
IgG1.  Isolated Fc and Fab fragments of IgG1  also failed to inhibit anti-IgG1 
plaques (not shown). These results suggest that anti-IgG1 antibodies recognize 
either conformational changes in IgG 1 caused by heat aggregation and antigen 
binding or, perhaps more likely, recognize native IgG1  with low affinity such 
that clustering of IgG1 molecules is required for high avidity binding. 
Twice-immunized A/J  mice produce at  least  two  different  specificities  of 
autoantibody, one that recognizes both  mouse IgG1  aliotypes (Ig4  a and Ig4  b) 
and another that  recognizes only Ig4L  Plaques of both  specificities could be 
inhibited entirely by the presence of 100 #g/ml heat-aggregated Ig4  a antibody 
in the plaque assay  chamber (Fig.  4).  An  independent confirmation of these 
results is detailed in Table I, which shows that hyperimmune A/J serum contains 
a higher level of anti-Ig4  a hemagglutinating activity than anti-Ig4  b activity. We 
consistently found that in spleens from Ig4  a strain  mice producing anti-IgG1, 
anti-Ig4  b PFC levels were lower than anti-Ig4  ~ PFC levels (Table II). The reverse 
was true in one set of Ig4  b mice tested. 
It has been noted that probably a very large fraction of B cells in both mice 
(9) and humans (28) are specific for self-Ig. Therefore one interpretation of our 
results indicating that secondary immunization triggers autoanti-IgG production 
is  that  the  boosting  antigen  causes  production  of antibody  that  cross-reacts 
between the foreign antigen and autologous IgG. This rather remote possibility 
is clearly ruled out by the results shown in Fig.  4. Detection of anti-IgG PFC 
TABLE  II 
Anti-IgG1 is Produced in Response to Secondary Antigenic Stimulation 
IgM anti-  PFC/ 
Strain  Priming Ag*  Boosting Ag  IgG 1  spleen  s 
Anti-Ig4*  Anti-Ig4  s 
A/J  OVA  OVA  130,606  72,618 
OVA  DNP-KLH  1,000  ND 
DNP-KLH  OVA  533  1,066 
DNP-KLH  DNP-KLH  57,600  ND 
BALB/c  OVA  OVA  36,800  23,200 
DNP-KLH  OVA  800  0 
C57B1/6  OVA  OVA  22,400  24,000 
DNP-KLH  OVA  2,527  8,114 
(BALB/c x  A/J)FI  OVA  OVA  92,800  45,600 
DNP-KLH  OVA  589  0 
* Mice were immunized intraperitoneally with 0.2 mg of either DNPrKLH or OVA in CFA, rested 
for 2 mo, and boosted 3 d before the assay with 30 ttg of either antigen in saline. 
s  Assays were done 3 d after the second injection. Each group consisted of three mice. 
ND, not determined. 536  ENHANCING  ANTIBODY  INDUCTION  IN  MICE 
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FIGURE 4.  Inhibition of A/J  IgM anti-IgG1 plaques.  Spleen cells pooled from three  A/J 
mice twice immunized with OVA were used as a source of anti-IgG 1 producing cells. Inhibition 
ofanti-lg4" plaques by: unaggregated Ig4  ~ (A), heat aggregated Ig4" (A), OVA (.). Inhibition 
a  b  by heat aggregated Ig4  of anti-lg4  plaques (ll), anti-NIP plaques (Q). 
from the  spleens of mice immunized twice with  OVA  was  unaffected by  the 
presence of 2.5 mg/ml OVA in the plaquing chamber. 
We obtained several monoclonal autoanti-IgG1  producing cell lines, derived 
from both mouse and rat, using somatic cell fusion techniques. Table III shows 
that of five monoclonal anti-IgG1  antibodies derived from Ig~-strain mice, four 
recognize Ig4  ~ exclusively and one recognizes both Ig4  a and Ig4  b. As yet we have 
not found a hybridoma that produces an antibody specific for any of the other 
mouse immunogiobulin isotypes. None of the rat antibodies tested could distin- 
guish between mouse IgG1 allotypes. 
Portion of the IgG1 Molecule Recognized by anti-IgG1.  We were able to localize 
the region of the IgG1  molecule that is bound by autoantibody from hyperim- 
munized mice to the Fc region. Three pieces of evidence support this conclusion. 
First, F(ab)'z IgG 1-coated erythrocytes were not agglutinated by a hyperimmune 
serum pool from A/J mice that had high titer against IgGl-coated cells (Table 
III). Second, none of the five mouse monoclonal anti-IgG 1 antibodies was capable 
of agglutinating  F(ab)'2  coated erythrocytes (Table  III).  Finally, in spleens in 
which very  large  numbers of anti-IgG1  antibody-forming cells were  detected 
using  IgGl-coated  cells,  no  cells  were  found  that  produced antibody  against NEMAZEE  AND  SATO 
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Isotype Specificity of Polyclonal and Monoclonal RF 
537 
Name  Source  Type 
Hemagglutination titer* vs. cells coated with: 
IgG 1 
Ig4*  ig4  b  F(ab)'2 
-Ig4* 
IgG2a  IgG2b  IgG3 
411H12  A/J  IgG3  213  0  0  0  0  0 
Y  BALB/c  IgM  >212  0  0  0  0  0 
P  BALB/c  lgM  >212  0  0  0  0  0 
G  BALB/c  IgM  >212  >212  0  0  0  0 
R  BALB/c  IgM  >212  0  0  0  0  0 
22C9  CD rat  IgM  215  216  0  0  0  0 
24C5  CD rat  IgM  >212  >212  0  0  0  0 
24D3  CD rat  IgM  >212  >212  0  0  0  0 
25C11  CD rat  IgM  >212  >2 ~2  0  0  0  0 
A/J  Normal serum  <2  ND  <2  <2  <2  <2 
A/J  Hyperimmune serum  2 s  ND  <2  <2  <2  <2 
* Titer of monoclonal antibodies assumes starting concentration of 1 mg/ml pure protein. 
ND, not determined. 
F(ab)'2-coated cells (Fig. 1). This result indicates that anti-antibodies of the type 
described by Milgrom and associates (29, 30), which are found in some human 
sera and bind to F(ab)'2 fragments that are bound to antigen, are not produced 
to any great extent in hyperimmunized mice. 
Isotype of Anti-IgG1 Material.  We  found  that  the  predominant  isotype  of 
autoanti-IgG1  was  IgM.  We  determined this  by  using  the  plaque  assay  we 
developed to  look for  anti-IgG1  producing cells  of different isotypes in  the 
spleens of A/J mice. We were fortunate to have available hybridomas producing 
monoclonal anti-IgG1  of either the  IgM  or IgG3  class  to determine optimal 
conditions for development of anti-IgG1 plaques. We found that IgM anti-IgG1 
plaques form without additional "developing" antisera. Indeed anti-# sera inhibit 
these plaques to the same extent as they inhibit IgM anti-erythrocyte plaques. 
IgG3 anti-IgG1 plaques could be visualized with the addition of anti-7-3-specific 
antiserum at a concentration that is also optimal for the detection of IgG3 anti- 
erythrocyte  plaques.  Thus  standard  developing antisera  used  for  hemolytic 
plaque assays need not be retitrated for use in detection of RF PFC. Using these 
conditions we could find no evidence for the production of IgG2a-, IgG2b-, or 
IgG3-anti-IgGl  antibodies in unimmunized or hyperimmunized A/J mice, in- 
cluding mice that were immunized repeatedly with antigen (data not shown). 
Clearly some IgG3 anti-IgG1 may be produced since we obtained a hybridoma 
line derived from a  hyperimmune A/J  mouse that produces antibody of this 
kind (Table  III).  However, the magnitude of the IgG3 anti-IgG1  response in 
hyperimmune mice must be small relative  to  the IgM anti-IgG1  response.  It 
should be noted that assay  conditions that allow detection of IgG3 anti-IgG1 
PFC also reveal all IgM anti-IgG1  PFC. Therefore, in order for the IgG3 PFC 
to be reliably detected they must be present in numbers not less than about 10% 
of the number of IgM anti-IgG1 PFC. 
In one experiment (Fig. 5) in which an accelerated immunization schedule was 538  ENHANCING  ANTIBODY  INDUCTION  IN  MICE 
300 
7o' 
60 
5O 
4q 
3O 
~o 
% 
lO  IgM anti-DNP 
lgM anti-lgG1 
1 
3  5  ?  9  11 
Day 
anti-DNP 
FIGURE 5.  Production of IgM anti-IgG1 in A/J  mice twice immunized with DNPsOVA. 
Mice were immunized first with 100 #g of protein in CFA and then boosted 10 d  later with 
30 .g of the protein in saline. Shown are anti-DNP and anti-IgGl PFC responses various days 
after the second injection. IgG anti-DNP (O), IgM anti-DNP (B), IgM anti-IgG1 (&), IgA anti- 
IgG 1 (~). Each time point represents the mean determination of duplicate samples taken from 
a pool of three spleens. 
used, we detected a significant number (-~ 10,000) of IgA anti-IgG1  PFC in the 
spleens of A/J mice 3 d after secondary antigenic stimulation with DNPsOVA, 
however we were unable to ascertain whether IgA anti-IgG1  hemagglutinating 
material was present in the sera of the mice. In a number of other experiments 
using OVA as the antigen we found no difference in the number of anti-IgG1 
PFC detected in the presence or absence of anti-a serum. 
To confirm our plaque assay results indicating that the bulk of the anti-IgG1 
produced in hyperimmunized mice is of the IgM class,  we analyzed the physi- 
ochemical properties of the anti-IgG1 hemagglutinating activity of hyperimmune 
sera.  Fig.  6  shows that >95%  of the hemagglutinating activity of pooled sera 
from A/J mice immunized three times with ovalbumin is excluded by Sephadex 
G-200  indicating  the  material  has  a  molecular weight  in  excess of 500,000 2.0 
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FIGURE 6.  Sephadex G-200 gel  filtration of A/J anti-OVA serum.  One  ml of serum  was 
applied to a 50 cm x  1.2 cm column equilibrated with PBS. Anti-IgG1 titers were determined 
as described in Materials and Methods. Anti-OVA titers were determined by hemagglutination 
of OVA-coupled sheep erythrocytes. Mice were immunized with 200 #g OVA on CFA on day 
0, and boosted with 30 #g in saline on day  10. Serum was harvested and pooled from five 
mice 7 d  after the second injection. Optical density at 280 nm (J~), anti-lgG1 agglutination 
(11), anti-OVA agglutination (&), anti-F(ab')2 IgG1 agglutination (A). 
daltons. Most of the anti-OVA activity appears to be IgG, running at an apparent 
molecular weight of <200,000 daltons. The result of DEAE-cellulose chroma- 
tography of hyperimmune serum is shown in Fig. 7. Anti-IgG1 activity is eluted 
at a relatively high salt concentration characteristic of IgM (150 mM), whereas 
the anti-OVA  material  is eluted at  a  much lower salt concentration (50-100 
mM), typical of IgG. 
Discussion 
We have presented evidence that strongly suggests that immune complexes 
consisting of circulating IgG and injected antigen can induce in vivo production 
of autoanti-IgG1. We wish to view the RF-like antibodies produced using this 
system in terms of the enhancer antibody concept, that is, as molecules whose 
production is induced by immunogenic determinants of immune complexes and 
whose preferential specificity is for immune complexes. Although self molecules 
are  recognized by  the  RF-like antibodies,  no breakdown of self tolerance  is 540  ENHANCING  ANTIBODY  INDUCTION  IN  MICE 
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FIGURE 7.  DEAE-cellulose ion exchange chromatography of hyperimmune A/J anti-OVA 
serum. 50 ~1 of serum was diluted in 2 ml of 10 mM Na phosphate buffer, pH 7.5 and applied 
to a  1-ml column equilibrated in the same buffer. Protein was eluted with a linear gradient of 
0-0.3 M NaCI in  10 mM Na phosphate, pH 7.5. A group of five mice was immunized with 
200, 30, and 100 t~g OVA 25, 18, and 7 d, respectively, before serum was taken. For the first 
injection the antigen was emulsified in CFA, the antigen was diluted in saline for the next two 
injections. 
necessarily implied (Fig. 4), and the response is terminated when the antigen is 
cleared,  underscoring the important contribution of foreign matter in the re- 
sponse. This work shows that secondary immunization of mice with a wide variety 
of protein antigens can result in autoanti-IgG production. Similar experiments 
by others (31, 32) using rabbits hyperimmunized to whole bacteria have yielded 
similar  results.  We  have  extended  this  analysis  by  assessing  the  isotype  and 
aliotype specificities of RF produced in hyperimmunized animals. The striking 
result is that the range of anti-IgG specificities expressed is very limited. In A/J 
mice virtually all of the RF produced is IgM anti-IgG1  Fc. 
We  have  developed a  modified  hemolytic plaque  assay  to  detect  antibody 
forming cells that is similar in design to RF-specific plaque assays used by others 
(26).  Our  modifications permit direct detection of autoantibody-forming cells 
and allow  us to determine isotype specificity of autoanti-IgG.  This technique 
should be particularly useful for studying the RF response in vitro. 
The total number of immunoglobulin idiotypes involved in the RF response 
studied here  is potentially quite  small because of the restricted  nature  of the 
antibody specificities produced. We know, however that the anti-IgG1 responses 
in a  number of Ig4  a allotype strains  that  we have  studied is not idiotypically 
homogeneous because at least two subspecificities exist, one that recognizes Ig4  a 
only and one that sees a determinant common to both Ig4  a and Ig4  b. No purely 
anti-Ig4 b responses were observed in these mice. This is consistent with the idea 
that in hyperimmunized animals, immune complexes behave similarly to antigens 
of  other  types  in  the  sense  that  they  elicit  an  exquisitely  specific  antibody 
response. However the reason that autoantibody is produced against only some 
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It is also curious that very little switching of IgM to IgG occurs in the anti- 
IgG 1 response in hyperimmunized mice, even after multiple exposure to immune 
complexes during repeated immunizations. This type of immune response pat- 
tern is unusual, and is found primarily in experimental systems that utilize the 
so-called T  cell-independent antigens (33,  34).  It is possible that immune com- 
plexes can also behave like T-independent antigens. 
Two  alternative  explanations  for  the  anti-IgG1  specificity  of  the  RF  are 
possible: 
(a) The expressed specificities may be determined by the relative numbers of 
B cells of different anti-IgG specificities present at the time of stimulation. In 
this case the anti-IgG1  specificity of the anti-IgG response of twice-immunized 
A/J mice would be due to the fact that, in these mice, virtually all of the B cells 
capable of reacting to the IgG portion of immune complexes are  specific for 
IgG1. It has been demonstrated that in many cases B cell mitogens can induce 
the production of large amounts of RF (9-12). This is presumably because some 
RF specificities are highly represented in the B cell repertoire. One study showed 
quite clearly a  nonrandom distribution of anti-IgG specificities found among a 
number of hybridoma lines derived from LPS-induced B cell blasts. Most of the 
anti-IgG clones were specific for IgG1  or IgG2a. However, it is possible that in 
this study the procedures used to produce and screen the hybridomas for anti- 
IgG activity could have contributed to this result (35). 
(b)  Alternatively,  IgG1  may be inherently more autoimmunogenic than  the 
other IgG isotypes and thus favor the production of autoanti-IgG1  despite the 
fact  that  the  relative  numbers  of potentially reactive  B  cells  specific  for  the 
various IgG subclasses may be comparable. This possibility appears to be plausible 
on the basis of indirect evidence. IgG1 differs fundamentally from other mouse 
IgG  isotypes  in  that  it  does  not  fix  complement (36).  This  fact  is  especially 
intriguing because of the demonstrable Fc specificity of the anti-IgG 1 produced, 
and suggests that the immune complexes that induce RF production are those 
that have not fixed complement. It is unlikely that the IgG1  preference of the 
autoanti-IgG of antigen-boosted A/J mice is the result of the relative amounts 
of the  various  IgG  subclass  antibodies  produced  in  response  to  the  primary 
immunization with antigen, because relatively large amounts of IgG2a and IgG2b 
are produced along with IgG 1 subsequent to immunizations with protein antigens 
in CFA (Fig. 3 and unpublished results). 
Although it appears that the autoanti-IgG described here is induced by anti- 
gen:antibody complexes it  is  by  no  means clear  that  the  resulting antibodies 
recognize conformational changes in the IgG due to antigen binding. Indeed, in 
two studies in which the relative affinities of the binding sites of human rheu- 
matoid factors to native or aggregated IgG were checked, no significant differ- 
ences were found (37, 38). 
Although in a strict sense the autoanti-IgG1 response we have characterized is 
autoimrnune since it is specific for self molecules, we believe that it differs from 
other autoantibody  responses and  is a  result,  rather  than  a  cause,  of disease. 
Similar views were put forward by Kunkel and Tan (39). Our results point to a 
simple explanation for the association of RF with autoimmune disease. Because 
production of anti-IgG1  is likely caused by immune complexes containing IgG1, 542  ENHANCING  ANTIBODY  INDUCTION  IN  MICE 
any situation in which both antigen and IgG 1 antibody to the antigen are present 
will cause RF-like enhancers to be produced. In humans, RF-like antibodies can 
be found during severe infections but are usually present transiently, presumably 
because the antigen is cleared quickly (40, 41). This is analogous to the type of 
pattern we see in the experiment shown in Fig.  2.  In autoimmune diseases in 
which antibodies are produced against self-determinants, new self antigens are 
constantly being produced or expressed. Thus immune complexes, either circu- 
lating or tissue bound, would be expected to be present transiently, presumably 
because the antigen is cleared quickly (40, 41). This is analogous to the type of 
pattern we see in the experiment shown in Fig.  2.  In autoimmune diseases in 
which antibodies are produced against self determinants, new self antigens are 
constantly being produced or expressed. Thus immune complexes, either circu- 
lating or tissue bound, would be expected to be present chronically and RF-like 
enhancers would also be found consistently in response to these complexes. Since 
RF-like antibodies are generally IgM and fix complement efficiently, they could 
clearly contribute to the pathology without necessarily initiating it. This scheme 
fits  relatively  well  with  the  known  fact  that  the  appearance  of RF  is  closely 
correlated  with  both  the  duration  and  the  intensity of a  number  of different 
autoimmune diseases (42, 43).  It has been shown recently that passive transfer 
of anti-collagen type II antibody can induce rheumatoid arthritis in rats (44). We 
would predict the RF-like enhancer production rapidly follows the introduction 
of the anti-collagen antibody in these rats and that these two types of antibodies 
operate synergistically to destroy self tissue. 
We have made the point elsewhere that autoanti-IgG may have both regulatory 
and effector roles in the normal immune response (4).  These speculations seem 
all the more justified in view of the findings of this study pointing to the fact 
that, in terms of both quantity and frequency of appearance, autoreactive IgM 
anti-IgGl-producing  cells  in  mice  appear  to  be  "normal."  Clarkson  and  co- 
workers  (45)  have  presented  evidence  indicating  that  RF-like  materials  may 
contribute to the ability of young rats to combat parasitic infections. This may 
be  but  one  of many  examples  of the  beneficial  effects of RF-like  enhancing 
antibody. 
Summary 
A/J  mice were found to produce autoreactive IgM anti-IgG1  in response to 
secondary immunization with a  number of protein antigens.  No anti-IgG1  was 
produced after a  single such immunization, indicating that antigen: IgG1  anti- 
body complexes were responsible for inducing the autoreactive response. The 
size of the anti-IgG1  response was in some cases massive and of the same order 
of magnitude as the response to the foreign immunizing material. No significant 
anti-IgG2a, anti-IgG2b, or anti-IgG3 response was found in mice producing anti- 
IgG 1. Virtually all of the anti-IgG 1 material produced was of the IgM class and 
bound to the Fc region of autologous IgG1. A component of the anti-IgG1  was 
shown to be able to distinguish between the two mouse IgG 1 allotypes. 
These results suggest that self-reactive anti-IgG is a  common component of 
the secondary immune response of mice that may have powerful physiological 
and immunoregulatory effects. NEMAZEE AND  SATO  543 
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